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ABSTRACT 
 
Clear cell renal cell carcinomas (ccRCC) represent 70% of renal cancers and several clinical and 
histolopathological factors are implicated in its prognosis. We recently demonstrated that the 
overexpression of PAR-3 protein encoded by the PARD3 gene could be implicated in renal 
oncogenesis. The object of this work was to study the association of intratumoral PAR-3 expression 
with known prognostic parameters and clinical outcome.  
In this aim, PAR-3 expression was assessed by immunohistochemistry in ccRCC tumors of 101 
patients from 2003 to 2005. The immunostaining of PAR-3 was scored either as membranous (mPAR-
3) or as both membranous and cytoplasmic (cPAR-3). 
Cytoplasmic PAR-3 was significantly associated with worse histopathological and clinical prognostic 
factors: Fuhrman grades 3 and 4, tumor necrosis, sarcomatoid component, adrenal invasion, renal and 
hilar fat invasion, eosinophilic component, a non-inactivated VHL gene, higher tumor grade, lymph 
node involvement, metastasis and worse clinical Eastern Cooperative Oncology Group (ECOG) and S 
classification scores. After multivariate analysis, two parameters were independently associated with 
cPAR-3: necrosis and eosinophilic components. In addition, cPAR-3 patients had shorter overall and 
progression free survivals independently from strong prognostic validated factors like metastases. 
A cytoplasmic expression of PAR-3 is therefore implicated in worse clinical and pathological cancer 
features in ccRCC and could be useful to identify patients with high risk tumors. 
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MAIN TEXT 
 
INTRODUCTION 
Renal cell carcinoma (RCC) is by far the most widely spread kidney malignancy, and its most frequent 
histological sub-type, clear cell renal cell carcinoma (ccRCC), represents about 70% of RCC [1,2]. 
Several prognostic factors have been described and validated in ccRCC, most of them being 
histological factors, essentially the Fuhrman nuclear grade, the presence of a sarcomatoid component, 
tumor necrosis, and invasion of the renal or hilar fat by tumor cells [1,3]. Chromosomal aberrations 
have also been described; losses of chromosomes 9p and 14 and gains of chromosome 8 are 
rearrangements associated with worse prognosis [4-6]. More than 90% of sporadic ccRCC have a loss 
of function of the Von Hippel-Lindau (VHL) tumor suppressor gene located on chromosome 3p; and 
tumors with this gene involvement have in opposite a better outcome [4,7]. When ccRCC is diagnosed 
at an early stage the optimal treatment of localized tumors is surgical resection by radical or partial 
nephrectomy [8], however approximately 20% of patients are not diagnosed until their disease is 
advanced or metastatic and one third of patients will develop metastases after initial surgery [9]. 
Immunotherapy was the established therapy for patients with metastatic ccRCC [10], and since 2005 
the understanding of the underlying molecular mechanisms in the oncogenesis of ccRCC led to the 
development of drugs that target molecular pathways involved in tumor development such as vascular 
endothelial growth factor receptor (VEGFR) or mTOR inhibitors [11,12]. 
Recently, we found a significant 1 Mb gene amplification of the 10p11.21 locus encompassing the 
partition-defective 3 gene (PARD3), in addition to its protein overexpression (PAR-3), in a cell line 
derived from a ccRCC tumor of worse clinical outcome [13]. PAR-3, belongs to a partition defective 
complex that controls polarity, which is mainly composed of PAR-3, PAR-6 and atypical protein 
kinase (aPKC) [14]. In mammalian epithelial cells this complex plays a role in controlling apical-basal 
polarity, asymmetric cell division, and directional cell migration. It is also believed that PAR proteins 
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may be involved in multiple aspects of oncogenesis as a relationship exists between polarity 
dysfunction and cancer progression [14-16]. 
Defective or overexpressed PAR-3 proteins have been described in other cancers related to tumor 
development or metastases formation, including breast cancer [17,18], hepatocellular carcinoma[19], 
or skin tumors [20]. In ccRCC, along with less survival rates, we recently showed that the migration of 
tumor cells might be promoted by the overexpression of PAR-3 and that the cytoskeleton organization 
was significantly altered [13]. However, the clinical and pathological significance of PAR-3 have not 
been elucidated. Therefore we investigated PAR-3 expression in a cohort of 101 ccRCC tumors in 
relation to the clinicopathological and survival characteristics of respective patients. 
 
MATERIALS AND METHODS 
Patients and clinicopathological analysis 
101 patients who underwent surgery for clear cell renal cell carcinoma from 2003 to 2005 at our 
institution were included. The Human Ethics Committee of Rennes University School and Hospital 
approved this study. The pathology reports, as well as the clinical and follow-up data were 
retrospectively analyzed. Tumor slides of all patients underwent re-examination by the Department of 
Pathology. Histological factors were evaluated blindly and independently by 2 pathologists (NRL and 
JD). Each case was screened for the following pathologic parameters: the Fuhrman nuclear grade, 
tumor necrosis, sarcomatoid features, adrenal invasion, renal or hilar fat invasion, renal vein invasion, 
microscopic vascular emboli, and cystic and eosinophilic components.  
The clinical data collected was the following: age at diagnosis, sex, side, tumor size, T stage, N stage, 
M stage, and multifocality. The TNM stage of tumors was upgraded in accordance with the 2009 TNM 
classification [21]. Two clinical scoring systems, the Eastern Cooperative Oncology Group (ECOG) 
and the symptom based classification (S classification) were established and used to compare patients’ 
clinical conditions. Patients were stratified in two ECOG groups corresponding to a score of 0 or ≥ 1 
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[22,23], and two S classification groups S1 (asymptomatic) or S2-S3 (tumors with local or systemic 
symptoms) [24]. 
 
PAR-3 analysis 
 Immunohistochemistry 
For each renal carcinoma case, a representative slide of the tumor with the highest Fuhrman nuclear 
grade and the corresponding paraffin block were selected. PAR-3 expression was assessed by 
immunohistochemistry as previously described [13]. The reactivity of antibodies against PAR-3 
(dilution 1:50) was revealed with HRP-labeled polymer conjugated secondary antibodies using 
diaminobenzidine (DAB) as chromogen (Sigma-Aldrich, France). Antibody staining was observed 
using an Olympus BX51 microscope and images recorded with an Olympus DP70 camera. PAR-3 
tumor expression was independently evaluated (NRL), without knowledge of patient outcome. The 
pattern of PAR-3 staining was qualitatively identified as membranous (mPAR-3) or membranous and 
cytoplasmic (cPAR-3). Negative control was performed by omitting the primary antibody. 
 FISH 
FISH assays were performed on 16 verified tumor samples of cPAR-3 and m-PAR-3 cases as 
previously described [25]. The PARD-3 probe corresponded to a 400 kb BAC contig (RP11-14K21, 
RP11-981G17, RP11-113B5, RP13-404M3) containing this gene and labeled with Spectrum Green 
(Abbott, Rungis France). A control probe (RP11-142C8, RP11-106O122, RP11-16P8) was combined, 
hybridizing at the 10q26.13 locus and labeled with Spectrum Orange (Abbott). All slides were 
independently analyzed by two observers (FD and FC). 
 
VHL status analysis 
VHL gene mutation, deletion and methylation status were assessed as previously described [26]. Each 
tumor was classified in 2 groups, inactivated VHL if a mutation and deletion and/or hypermethylation 
was detected; otherwise tumors were classified as wild-type VHL. 
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Statistical analysis 
All analyses were conducted through procedures available in SAS 9.3 (SAS Institute, Cary N.C., 
USA). For a descriptive purpose, data was reported as mean and standard deviation or median, 25th 
and 75th percentiles for continuous variables and follow-up time; numbers and percentages of non-
missing values were used for categorical variables. Two-sided p-values from chi-square and t-tests 
assessed differences between cPAR-3 and mPAR-3 tumors; if needed Fisher exact test and Wilcoxon 
test were used instead. Maentel-Haenszel chi-square test (Ridit Scores) was used for ordinal variables 
(the S-System score). A logistic regression model with Firth's bias correction was run in which PAR-3 
status (cPAR-3 vs. mPAR-3 tumors) was regressed on the selected covariates, i.e. those covariates 
significant in the univariate analyses at the p = 0.15 level. A backward elimination procedure retained 
variables with a p < 0.05 level. The final model provided estimated probabilities for cPAR-3 according 
to different pattern of covariates. For overall survival and progression free survival, Kaplan-Meier 
method calculated product-limit survival estimates according to PAR-3 status and Log-rank test was 
used to compare survival distributions. Cox proportional hazards modeling was then applied. The 
multivariable model contained at the outset all covariates significant in the univariate analyses at the p 
= 0.15 level. We used a hand-made stepwise backward elimination process. The proportional hazard 
assumption was assessed also through graphical (Schoenfeld residuals analysis) as well as testing 
(using time-dependent variable) approaches. 
 
RESULTS 
Patients and tumor characteristics are summarized in Table 1. Our cohort consisted of 58 men (57 %) 
and 43 women (43 %). Mean age at diagnosis was 62.7 +/- 11.5 years. No difference in age or sex was 
observed between cPAR-3 and mPAR-3 tumors. The mean duration of follow-up was 59.5 months; the 
maximal duration was 72 months.  
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PAR-3 analysis 
Immunohistochemistry 
Immunohistochemical analysis of healthy kidney tissue showed that PAR-3 was localized at the apical 
border of tubular cells. A cytoplasmic staining of PAR-3 was observed in 51 out of 101 primary 
tumors (51.51 %). These cases contained cells with a cytoplasmic, strong and diffuse expression of 
PAR-3; whereas the immunostaining pattern of mPAR-3 tumors was membranous and diffuse (Figure 
1). Considering tumor heterogeneity, 21 cPAR-3 tumors presented different Fuhrman grades on the 
same slide. In these cases, a cPAR-3 expression was observed in high Fuhrman grades 3 and 4 
(including 11 sarcomatoid cases) whereas Fuhrman 2 areas showed only an mPAR-3 staining. In 
addition, no difference in PAR-3 immunostaining distribution in relation to the vascular supply was 
observed (data not shown). 
 
FISH 
PARD3 gene status was assessed to determine if a cytoplasmic PAR-3 expression was associated to a 
gene amplification. Interphase FISH analysis was performed on tissue sections of 13 cPAR-3 and 3 
mPAR-3 cases. For each tumor, a 2 red-2 green hybridization pattern was detected in at least 70% of 
the nuclei (Figure 1). Only one tumor showed 3 red and 3 green signals in 10% of the nuclei (data not 
shown). As a result, no amplification of the PARD3 gene was detected. 
 
Clinicopathological analysis  
Mean tumor size was 7.34 +/- 3.70 cm, with a significant difference between cPAR-3 and mPAR-3 
tumors (8.77 +/- 3.85 vs. 5.88 +/- 3.01 cm respectively; p < 10-4). Most histological prognostic factors 
were significantly associated to a cytoplasmic expression of PAR-3 (Figure 2): a higher nuclear 
Fuhrman grade 3 or 4 (p < 10-8), the presence of necrosis (p < 10-7), eosinophilic (p < 10-10) or 
sarcomatoid features (p < 10-5), renal or hilar fat invasion (p < 10-3 and p = 0.033 respectively), and 
exclusively the invasion by contiguity of the adrenal gland (p = 0.013). 
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cPAR-3 was associated to poor clinical parameters: higher T stages T3 or T4 (p < 10-3) as well as N1/2 
and M1 stages (p < 10-3 and p < 5x10-3 respectively). Tumors with T3/4 stages (48/101 cases) were 
mainly composed of Fuhrman grades 3 or 4 (43/48). Only 5 cases were of Fuhrman grade 2 and had 
mPAR-3 stainings. The 11 cases of nodal involvement were only observed in cPAR-3 tumors.  
Patients with tumors expressing a cytoplasmic PAR-3 had worse clinical scores: ECOG score ≥ 1 (p = 
0.018) and S classification scores S2 or S3 (p < 5x10-3). In opposite, cPAR-3 was not significantly 
related to multifocality, cystic component, renal vein invasion or microscopic vascular invasion. 
 
VHL status analysis 
Given the frequent VHL gene defective status in ccRCC, its inactivation was found in 63 cases 
corresponding to 28 cPAR-3 (55%) and 35 mPAR-3 (70%) cases. These cases were heterogeneously 
distributed within the 2 alleles as follows: 71 deletions, 13 promoter methylations, and 52 mutations. 
Data was not available in 7 cases due to technical failure. PAR-3 was more frequently cytoplasmic in 
the wild-type VHL group than in the inactivated VHL group (21/51 (41%) vs. 10/50 (20%); p = 0.048). 
 
Multivariate and survival analyses  
In multivariate logistic regression analysis, necrosis (OR = 5.5; 95%CI, 1.7 to 17; p = 0.0038) and the 
presence of an eosinophilic component (OR = 18; 95%CI, 4.8 to 70; p <.0001) were independently 
associated with cPAR-3 (Figure 2). Kaplan-Meier survival analysis showed a significant difference in 
both overall (p < 10-4) and progression-free survival (p < 10-4) between cPAR-3 and mPAR-3 tumors. 
cPAR-3 tumors had a median overall survival of 28 months and a median progression-free survival of 
11 months. In opposite, the median overall and progression-free survivals of mPAR-3 patients were 
not reached after a 72 month follow-up. At this time point, 64% of mPAR-3 patients were still alive 
compared to only 31% of cPAR-3 patients. Taking account of the T stage and presence of metastasis, 
PAR-3 was independently associated with a worse overall survival in multivariate analysis (p = 0.015, 
HR = 2.1, 95% Hazard Ratio Confidence Limits: 1.2 - 3.9). In addition, PAR-3 was an independent 
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factor for a worse progression-free survival (HR = 2.0; 95%CI, 1.2 to 3.6; p = 0.011) in a multivariate 
analysis adjusting for vascular emboli, metastasis and the ECOG score. A cytoplasmic PAR-3 
expression was also significantly associated with disease-related death (Figure 3). 
 
DISCUSSION 
The results of this study underscore that a cytoplasmic PAR-3 expression is a predictor of at-risk 
tumors, as is supported by worse clinical and histolopathological features and its association to 
reducing the survival rates of ccRCC patients. To our knowledge, this is the first study which describes 
PAR-3 expression profile as an independent factor of mortality in renal carcinoma. 
Cell polarity is regulated by proteins of the PAR complex which in mammalian epithelial cells play a 
role in controlling apical-basal polarity, asymmetric cell division, and directional cell migration [14-
16]. Mammalian tumors have been reported to aberrantly express PAR-3; its expression is significantly 
reduced in human invasive breast cancer [17], but is also down regulated in metastasis and associated 
with a higher tumor grade [18]. In hepatocellular carcinoma, an over-expression of PAR-3 can predict 
an increased incidence of extra hepatic metastasis and is associated with poor survival [19]. 
At a genetic level, cell lines and primary tumors of glioblastomas and squamous carcinomas including 
esophageal, head and neck, and lung squamous cell carcinomas have PARD3 deletions [27]. 
Conversely, Zitzelsberger et al. reported a PARD3 amplification using FISH technique in cell lines of 
radiation-transformed neoplastic retinal pigment cells [28]. This was also observed in a ccRCC cell 
line of our previous study [13]. Interestingly, FISH analyses performed on 13 cPAR-3 tumors herein 
demonstrated no gene amplification suggesting that post-transcriptional and/or translational events 
might be more frequently at the origin of a PAR-3 aberrant expression. The cPAR-3 tumors were 
related to a non-inactivated VHL status, which is associated to a worse prognosis. As VHL gene is 
widely implicated in ccRCC oncogenesis [7], the hypothesis of a possible intracellular interaction 
between PAR-3 and VHL will be further investigated. 
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Tumors exhibiting adverse pathological features were significantly associated with a cPAR-3 
expression, especially a higher Fuhrman grade and necrosis which are main features of worse outcome 
in ccRCC [1,3]. Moreover, an eosinophilic component, described to be more frequently observed in 
high grade ccRCC [29], was also significant in these tumors. The presence of necrosis can be related to 
a more important tumor proliferation rate. However, the molecular mechanisms associating these 
major pathological factors to a PAR-3 aberrant expression are unclear and need to be further 
elucidated. The association between sarcomatoid features and cPAR-3 tumors can be supported by the 
loss of intercellular adhesions and apico-basal polarity between epithelial cells, which may induce 
invasive cancers in relation to epithelial to mesenchymal transition [30]. 
Tumor size was significantly higher in cPAR-3 expressed ccRCCs, and could favor higher probability 
for extra-renal expansion, especially to the surrounding renal and hilar fat. These factors combined 
play a role in the T stage status, leading to more frequent T3 or T4 stages. In addition, the N and M 
stages were significantly higher in cPAR-3 tumors, which is consistent with our previous study 
suggesting that an over-expression of PAR-3 was associated with tumor cell migration [13]. This 
finding is also highlighted by a higher frequency of tumor invasion to the perirenal fat as well as to the 
adrenal gland by contiguity in cPAR-3 ccRCCs.  
Two clinical scores were used to evaluate patients at diagnosis [22-24]. The ECOG scale of cPAR-3 
patients was significantly higher than that of mPAR-3 patients, meaning that restriction in activity and 
performance in daily life was more frequent. Similarly, the S classification revealed more frequent 
symptomatic tumors in cPAR3 patients. Finally, the adjustment of survival rates data to other 
prognostic factors including metastases reinforced the fact that PAR-3 appears to be a strong 
independent predictor of poor overall and progression-free survivals. 
 
CONCLUSIONS 
Cytoplamic PAR-3 expressed ccRCCs are at significant risk of cancer progression and mortality. 
Biomarkers introduced into daily practice are essential for a personalized medical care in order to 
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predict clinical evolution. PAR-3 expression can be easily screened by immunohistochemistry in 
routine and the assessment of this expression may prove useful to identify high risk ccRCC patients 
even in absence of usual prognostic parameters. Further investigations need to be undertaken to 
determine its potential role as a therapy resistance biomarker adding value to existing nomograms. 
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TABLE/FIGURE LEGENDS 
Table.  
Patients and tumor characteristics 
Parameters cPAR-3: n (%) P 
Overall tumors (N = 101) 51 (50,5) 
 
Age at diagnosis, y 
 
.81 
 <60 (n = 41) 19 (46,3) 
 
 ≥60 (n = 60) 32 (53,3) 
 
Sex 
 
.55 
 Male (n = 58) 31 (53,4) 
 
 Female (n = 43) 20 (46,5) 
 
Multifocality 
 
.55 
 Neg (n = 89) 46 (51,7) 
 
 Pos (n = 12) 5 (41,7) 
 
Cystic component 
 
.46 
 Neg (n = 82) 43 (52,4) 
 
 Pos (n = 19) 8 (42,1) 
 
Fuhrman grade 
 
7.681 × 10−9* 
 F 1/2 (n = 32) 3 (9,4) 
 
 F 3/4 (n = 69) 48 (69,6) 
 
Necrosis 
 
6.863 × 10−8** 
 Neg (n = 43) 8 (18,6) 
 
 Pos (n = 57) 42 (73,7) 
 
 NA (n = 1) 1 (100) 
 
Sarcomatoid differentiation 
 
1.815 × 10−6* 
 Neg (n = 74) 26 (35,1) 
 
 Pos (n = 23) 21 (91,3) 
 
 NA (n = 4) 4 (100) 
 
Eosinophilic component 
 
2.025 × 10−11** 
 Neg (n = 38) 3 (7,9) 
 
 Pos (n = 60) 45 (75) 
 
 NA (n = 3) 3 (100) 
 
Adrenal invasion 
 
.0125* 
 Neg (n = 93) 43 (46,2) 
 
 Pos (n = 7) 7 (100) 
 
 NA (n = 1) 1 (100) 
 
Renal fat invasion 
 
2.017 × 10−4* 
 Neg (n = 62) 22 (35,5) 
 
 Pos (n = 39) 29 (74,4) 
 
Hilar fat invasion 
 
.0327 * 
 Neg (n = 67) 28 (41,8) 
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Parameters cPAR-3: n (%) P 
 Pos (n = 32) 21 (65,6) 
 
 NA (n = 2) 2 (100) 
 
Renal vein invasion 
 
.0897 
 Neg (n = 68) 30 (44,1) 
 
 Pos (n = 33) 21 (63,6) 
 
Microscopic vascular emboli 
 
.0528 
 Neg (n = 68) 29 (42,6) 
 
 Pos (n = 32) 21 (65,6) 
 
 Not available (n = 1) 1 (100) 
 
VHL status 
 
.0478 * 
 Inactivated (n =63) 28 (44,4) 
 
 Noninactivated (n = 31) 21 (67,7) 
 
 NA (n = 7) 2 (28,6) 
 
T stage 
 
6.680 × 10−4* 
 T1/2 (n = 53) 18 (34) 
 
 T 3/4 (n = 48) 33 (68,8) 
 
N stage 
 
5.347 × 10−4* 
 N0 (n = 90) 40 (44,4) 
 
 N 1/2 (n = 11) 11 (100) 
 
M stage 
 
.0035* 
 M 0 (n = 73) 30 (41,1) 
 
 M 1 (n = 28) 21 (75) 
 
ECOG score 
 
.0182* 
 0 (n = 69) 29 (42) 
 
 >1 (n = 32) 22 (68,8) 
 
S-System score 
 
.0018* 
 1 (n = 47) 15 (31,9) 
 
 2 (n = 26) 16 (61,5) 
 
 3 (n = 28) 20 (71,4) 
 
 
Table 1. Patients and Tumor characteristics 
Cytoplasmic PAR-3 expression cases compared to the whole group of ccRCC tumors, in relation to 
clinical and histological data: number of cases and percentages (*: p < 0,05, **: independent factor 
after multivariate analysis). 
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Figure 1. Comparative histological, immunostaining and FISH analysis of distinct cPAR-3 and 
mPAR-3 cases 
cPAR-3 (A, C, E) and mPAR-3 tumors (B, D, F) have different microscopic profiles. (A) sarcomatoid 
component is associated to necrosis and higher nuclear grade. (B) Classical aspect of a Fuhrman grade 
2 ccRCC. (C, D) Immunostaining showing cPAR-3 with immunolabeling located in the cytoplasm and 
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membrane of tumor cells, while mPAR-3 shows only a membranous staining. (E, F) FISH analysis 
showing no PARD3 amplification in both cPAR-3 and mPAR-3 tumors. 
 
 
 
Figure 2. Pathological and clinical features according to PAR-3 expression 
Percentage of samples displaying the indicated features within the mPAR-3 and cPAR-3 subgroups. 
cPAR-3 tumors are significantly associated to poor prognostic factors (*). Necrosis and eosinophilic 
components remain significant after multivariate analysis (§). 
(*: p < 0.05; §: significant in multivariate analysis) 
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Figure 3. PAR-3 expression and disease-related death 
Patients with cPAR-3 tumors have significantly shorter survival than those with tumors having only a 
membranous expression (p < 10-4). Values above the abscissa axis correspond to the number of 
patients still alive in each group (cPAR-3 and mPAR-3).  
